Seroatlas · Human Serome Atlas

PNMA2

Paraneoplastic antigen Ma2

Also known as: MA2, PNMA2_HUMAN, RGAG2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UL42
Gene
PNMA2
Ensembl
ENSG00000240694
Chromosome
8
Canonical length
364 aa
Protein class
Predicted intracellular proteins

OverviewNCBI Gene

Predicted to be involved in positive regulation of apoptotic process. Predicted to be located in nucleolus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

364 residues, UniProt reviewed canonical sequence.

>Q9UL42|PNMA2
     1  MALALLEDWC RIMSVDEQKS LMVTGIPADF EEAEIQEVLQ ETLKSLGRYR LLGKIFRKQE
    61  NANAVLLELL EDTDVSAIPS EVQGKGGVWK VIFKTPNQDT EFLERLNLFL EKEGQTVSGM
   121  FRALGQEGVS PATVPCISPE LLAHLLGQAM AHAPQPLLPM RYRKLRVFSG SAVPAPEEES
   181  FEVWLEQATE IVKEWPVTEA EKKRWLAESL RGPALDLMHI VQADNPSISV EECLEAFKQV
   241  FGSLESRRTA QVRYLKTYQE EGEKVSAYVL RLETLLRRAV EKRAIPRRIA DQVRLEQVMA
   301  GATLNQMLWC RLRELKDQGP PPSFLELMKV IREEEEEEAS FENESIEEPE ERDGYGRWNH
   361  EGDD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PNMA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.34
Highest tissue expression
114 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 114 nTPM
  • hypothalamus: 97 nTPM
  • basal ganglia: 83 nTPM
  • amygdala: 64 nTPM
  • hippocampal formation: 56 nTPM
  • midbrain: 36 nTPM

Single-cell type

  • other brain neurons: 130 nCPM
  • brain inhibitory neurons: 116 nCPM
  • brain excitatory neurons: 68 nCPM
  • pancreatic islet cells: 59 nCPM
  • ependymal cells: 53 nCPM
  • corticotrophs: 49 nCPM

Immune cell

  • basophil: 0.7 nTPM
  • naive B-cell: 0.1 nTPM
  • naive CD8 T-cell: 0.1 nTPM
  • neutrophil: 0.1 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM

Brain region

  • hypothalamus: 251 nTPM
  • cerebral cortex: 214 nTPM
  • basal ganglia: 176 nTPM
  • hippocampal formation: 125 nTPM
  • pons: 124 nTPM
  • thalamus: 124 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PNMA2.

Disease | AutoantibodyPubMed

Conditions in which antibodies against PNMA2 are reported. Each links to that disease's full target list.

Showing 8 of 11 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for PNMA2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

55 publications

Show 20 more of 55 total

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.07
gnomAD pLI
0
gnomAD missense Z
0.29
DepMap mean gene effect
0.11
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PNMA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PNMA2 as an antibody target. Whether an autoantibody or antibody against PNMA2 could matter depends on whether native PNMA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PNMA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PNMA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PNMA2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...